Table 2 Comparison of baseline characteristics according to group.

From: Characteristics of chronic obstructive pulmonary disease patients with robust progression of emphysematous change

 

Non-progression group

Rapid progression group

P-value

N = 163

N = 54

Age, years

72.2 ± 8.5

73.0 ± 8.2

0.54

Sex, female, N (%)

11 (6.8)

8 (14.8)

0.07

Smoking index, pack-years

54.1 ± 31.8

51.5 ± 28.9

0.60

Current Smoker, N (%)

14 (8.8)

5 (9.3)

0.92

Lung function

FEV1, ml

1838.7 ± 612.1

1713.7 ± 681.5

0.21

%FEV1, %

68.0 ± 19.6

67.3 ± 24.9

0.84

LAA%, %

13.0 ± 10.7

14.1 ± 9.3

0.51

WA%, %

54.3 ± 8.6

56.4 ± 8.6

0.12

Other Pulmonary Disease

Interstitial Pneumonia, (%)

17 (10.5)

9 (16.4)

0.25

Asthma, (%)

30 (18.4)

11 (20.4)

0.64

Laboratory values

Blood neutrophil count,

cells/mm3

3937.5 ± 1479.1

3937.5 ± 1646.6

0.60

Blood eosinophil count,

cells/mm3

226.9 ± 215.7

150.7 ± 89.5

0.01

SAA, µg/ml

11.7 ± 25.8

27.4 ± 99.7

0.08

CRP, mg/dl

0.26 ± 0.71

0.44 ± 1.41

0.23

Patient-reported outcomes

CAT score

11.7 ± 7.8

12.4 ± 8.3

0.53

SGRQ total score

25.9 ± 17.9

28.4 ± 18.5

0.42

Bronchodilator (%)

108 (73.0)

40 (72.7)

0.40

ICS, N %

42 (25.9)

13 (23.6)

0.74

  1. Data are presented as mean ± SD or number (%).
  2. FEV1 forced expiratory volume in 1 s, %FEV1 forced expiratory volume in 1 s as a percentage of predicted forced expiratory volume in 1 s, LAA% the ratio of low attenuation area to total lung volume, WA% the percentage of airway wall area, SAA serum amyloid A, CRP C-reactive protein, CAT chronic obstructive pulmonary disease assessment test, SGRQ St. George’s Respiratory Questionnaire, ICS inhaled corticosteroids.
Back to article page